Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
08 Fevereiro 2024 - 6:05PM
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it
will report fourth quarter and full-year 2023 financial results and
provide a corporate update on February 15, 2024. The company will
also host a conference call that day at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by
clicking here. Upon registering, each participant will
receive a dial-in number, and a unique access PIN. Each access PIN
will accommodate one caller.
Additionally, a listen-only webcast will be available by
clicking here.
A replay of the call will be available on the
Investors / Events tab of www.corcept.com.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol
modulation and its potential to treat patients across a wide
variety of serious disorders has led to the discovery of more than
1,000 proprietary selective cortisol modulators. Corcept’s advanced
clinical trials are being conducted in patients with
hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS)
and non-alcoholic steatohepatitis (NASH). In February 2012, the
company introduced Korlym®, the first medication approved by the
U.S. Food and Drug Administration for the treatment of patients
with Cushing’s syndrome. Corcept is headquartered in Menlo Park,
California. For more information, visit www.corcept.com.
CONTACT:Investor
inquiries:ir@corcept.comMedia inquiries:Communications@corcept.com
www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Corcept Therapeutics (NASDAQ:CORT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024